Fluvoxamine for the treatment of COVID-19

doi:10.1016/S2214-109X(22)00003-1

Comment

. 2022 Mar;10(3):e330.

doi: 10.1016/S2214-109X(22)00003-1.

Fluvoxamine for the treatment of COVID-19

Hyun Kim¹, Shannon Manzi², Joseph Gonzelez-Heydrich³, Jonathan Picker⁴

Affiliations

¹ Clinical Pharmacogenomics Service, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pharmacy, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: hyun.kim@childrens.harvard.edu.
² Department of Pharmacy, Boston Children's Hospital, Boston, MA 02115, USA.
³ Department of Psychiatry and Behavioral Sciences, Boston Children's Hospital, Boston, MA 02115, USA.
⁴ Clinical Pharmacogenomics Service, Boston Children's Hospital, Boston, MA 02115, USA; Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.

PMID: 35180410
PMCID: PMC8846602
DOI: 10.1016/S2214-109X(22)00003-1

Comment

Fluvoxamine for the treatment of COVID-19

Hyun Kim et al. Lancet Glob Health. 2022 Mar.

. 2022 Mar;10(3):e330.

doi: 10.1016/S2214-109X(22)00003-1.

Authors

Hyun Kim¹, Shannon Manzi², Joseph Gonzelez-Heydrich³, Jonathan Picker⁴

Affiliations

¹ Clinical Pharmacogenomics Service, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pharmacy, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: hyun.kim@childrens.harvard.edu.
² Department of Pharmacy, Boston Children's Hospital, Boston, MA 02115, USA.
³ Department of Psychiatry and Behavioral Sciences, Boston Children's Hospital, Boston, MA 02115, USA.
⁴ Clinical Pharmacogenomics Service, Boston Children's Hospital, Boston, MA 02115, USA; Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.

PMID: 35180410
PMCID: PMC8846602
DOI: 10.1016/S2214-109X(22)00003-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

Fluvoxamine for the treatment of COVID-19.
Marzolini C, Marra F, Boyle A, Khoo S, Back DJ. Marzolini C, et al. Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1. Lancet Glob Health. 2022. PMID: 35180411 Free PMC article. No abstract available.

Comment on

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida APFG, Callegari ED, de Figueiredo Neto AD, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ; TOGETHER investigators. Reis G, et al. Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28. Lancet Glob Health. 2022. PMID: 34717820 Free PMC article. Clinical Trial.
Fluvoxamine for the treatment of COVID-19.
Boulware DR, Abassi M. Boulware DR, et al. Lancet Glob Health. 2022 Mar;10(3):e329. doi: 10.1016/S2214-109X(21)00590-8. Lancet Glob Health. 2022. PMID: 35180409 Free PMC article. No abstract available.

Cited by

Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
Yu CL, Carvalho AF, Thompson T, Tsai TC, Tseng PT, Hsu CW, Tu YK, Yang SN, Hsu TW, Yeh TC, Liang CS. Yu CL, et al. Int J Environ Res Public Health. 2023 Feb 24;20(5):4088. doi: 10.3390/ijerph20054088. Int J Environ Res Public Health. 2023. PMID: 36901099 Free PMC article. Review.

References

1. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–e51. - PMC - PubMed
1. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127–134. - PMC - PubMed
1. Friedrich DC, Genro JP, Sortica VA, et al. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLoS One. 2014;9 - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources

[1] Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–e51. - PMC - PubMed

[2] Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–e51. - PMC - PubMed

[3] Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127–134. - PMC - PubMed

[4] Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127–134. - PMC - PubMed

[5] Friedrich DC, Genro JP, Sortica VA, et al. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLoS One. 2014;9 - PMC - PubMed

[6] Friedrich DC, Genro JP, Sortica VA, et al. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLoS One. 2014;9 - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Fluvoxamine for the treatment of COVID-19

Affiliations

Fluvoxamine for the treatment of COVID-19

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources